PIK3CD and neoplasm: SHR8443 was well tolerated when administered orally and displayed broader and stronger antitumor activity than BEZ235 against tumor xenografts formed from PTEN-null U-87MG and PC-3 cells, KRAS-mutated A549 cells, PI3K-mutated BT-474 cells, and trastuzumab-resistant BT-474/trastuzumab cells.